Forte Biosciences (FBRX)
(Delayed Data from NSDQ)
$0.52 USD
-0.01 (-1.89%)
Updated Jul 9, 2024 03:58 PM ET
After-Market: $0.50 -0.02 (-3.85%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
FBRX 0.52 -0.01(-1.89%)
Will FBRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FBRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FBRX
What Makes Forte Biosciences (FBRX) a New Buy Stock
FBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for FBRX
Forte Biosciences initiated with bullish view at Rodman & Renshaw
Forte Biosciences initiated with bullish view at Brookline, here's why
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update